타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Bimzelx (bimekizumab) |
Overview Company | UCB |
Overview Modality | ANTIBODY |
Overview Target | IL-17A / IL-17F |
Overview Indication | Plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | IL-17F contributes independently to tissue inflammation, so blocking it as well raises the ceiling on complete skin clearance. |
Positioning Known limitation | Anti-drug antibodies and non-IL-17-driven inflammatory phenotypes. |
Positioning Development positioning | 1L–2L biologic |
MoA Mechanism | Binds IL-17A and IL-17F, preventing engagement of the IL-17RA/RC complex and shutting down downstream keratinocyte and synovial inflammatory signaling more completely than IL-17A blockade alone. |
MoA Biomarker | PASI/IGA response, hs-CRP in axial disease. |
Toxicology Species | Cynomolgus monkey |
Toxicology Major finding | Oral candidiasis is the signature toxicity of IL-17F co-blockade and occurs in roughly 10–20% of patients. Upper respiratory infection is common; inflammatory bowel disease requires monitoring. |
Toxicology CRS | N/A |
Clinical Safety signal | Oral candidiasis is the signature toxicity of IL-17F co-blockade and occurs in roughly 10–20% of patients. Upper respiratory infection is common; inflammatory bowel disease requires monitoring. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Bimzelx (bimekizumab) |
Overview Company | UCB |
Overview Modality | ANTIBODY |
Overview Target | IL-17A / IL-17F |
Overview Indication | Plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | IL-17F contributes independently to tissue inflammation, so blocking it as well raises the ceiling on complete skin clearance. |
Positioning Known limitation | Anti-drug antibodies and non-IL-17-driven inflammatory phenotypes. |
Positioning Development positioning | 1L–2L biologic |
MoA Mechanism | Binds IL-17A and IL-17F, preventing engagement of the IL-17RA/RC complex and shutting down downstream keratinocyte and synovial inflammatory signaling more completely than IL-17A blockade alone. |
MoA Biomarker | PASI/IGA response, hs-CRP in axial disease. |
Toxicology Species | Cynomolgus monkey |
Toxicology Major finding | Oral candidiasis is the signature toxicity of IL-17F co-blockade and occurs in roughly 10–20% of patients. Upper respiratory infection is common; inflammatory bowel disease requires monitoring. |
Toxicology CRS | N/A |
Clinical Safety signal | Oral candidiasis is the signature toxicity of IL-17F co-blockade and occurs in roughly 10–20% of patients. Upper respiratory infection is common; inflammatory bowel disease requires monitoring. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
추천 비교
추천 비교